Tandem Diabetes Care (Nasdaq:TNDM) recently announced the appointment of Rebecca Robertson as the chair of its board of directors.
Robertson initially joined Tandem’s board as an independent director in January 2019. She succeeds Kim Blickenstaff as chair. Blickenstaff intends to continue as a member of the board.
“We’re deeply grateful to Kim for his instrumental contributions to Tandem since 2007, serving first as our CEO then as chair for the past 4 years,” said John Sheridan, Tandem president and CEO. “His strategic vision and mission-driven focus has helped to build and shape Tandem from a venture-backed start-up to a worldwide leader in diabetes care.”
Robertson’s track record spans roles at medical device companies including engineer, entrepreneur, executive and board member. She founded Versant Ventures for investing in medical devices and diagnostics, serving as general partner since 1999. Before Versant, she served as SVP at Chiron Diagnostics.
She also co-founded and served as VP at Egis and held senior management positions at Johnson & Johnson’s Lifescan. Through Longridge Business Advisors, Robertson has provided business advisory and board services since April 2017.
Blickenstaff called Robertson a “natural choice” for the position of board chair at Tandem Diabetes Care.
“I am honored to be named chair and am committed to maximizing the opportunities we have at Tandem,” said Robertson. “Tandem continues to deliver life-changing solutions to people around the world and has a compelling pipeline of products in development that offer near and long-term growth potential. I believe our technology can change the face of therapy for people with diabetes and I’m excited to be part of what comes next.”
